Expression of ROR1 has also been reported in a range of malignancies, including chronic lymphocytic leukaemia, mantle cell leukaemia, some myeloid leukaemias, melanoma, triple-negative breast cancer, neuroblastoma, non-small cell lung cancer and tumours derived from the ovary, bowel, stomach, pancreas, prostate, kidney and endometrium [42]. Here, ROR1 is linked to triple-negative breast carcinoma.